Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
More subcutaneous fat may mean better outcomes for biliary tract cancer patients on immunotherapy. A new study found that higher subcutaneous adiposity was linked to significantly longer progression-free and overall survival in advanced biliary tract cancer patients receiving immune checkpoint inhibitors — but not in those on chemotherapy alone. Researchers say subcutaneous fat may be a useful prognostic marker for this patient group.
Body fat distribution may predict survival in biliary tract cancer patients on immunotherapy
Not all fat is created equal — and for patients with advanced biliary tract cancer (BTC) on immunotherapy, having more subcutaneous (under-the-skin) fat may actually be a survival advantage. A new study published in the Journal of Gastroenterology found that higher subcutaneous adiposity was significantly associated with longer progression-free survival (PFS) and overall survival (OS) in patients receiving immune checkpoint inhibitors (ICIs) alongside chemotherapy.
Researchers from Japan's Cancer Institute Hospital retrospectively analyzed 247 patients with advanced BTC. Those in the ICI cohort (n=68) with higher subcutaneous adipose tissue index (SATI) showed markedly better survival outcomes, while no such association was seen in the 179 patients treated with chemotherapy alone.
Key Takeaways
Why it matters: As ICI-based regimens become standard in advanced BTC, identifying who benefits most is critical. Subcutaneous adiposity — measurable via routine CT scans — could become a practical, non-invasive prognostic tool to help guide treatment decisions.
